1. Scrip

Writedowns and US decline hit Dr Reddy's third quarter

 
• By Anju Ghangurde

Dr Reddy’s Laboratories reported a loss of Rs5.2 billion ($112 million) for the third quarter ended December 31st, 2009, hit by writedowns in its German business, Betapharm, and a decline in revenues from the US. Total revenues for the period fell by 6% to Rs17.3 billion.

Dr Reddy’s Laboratories reported a loss of Rs5.2 billion ($112 million) for the third quarter ended December 31st, 2009, hit by writedowns in its German business, Betapharm, and a decline in revenues from the US. Total revenues for the period fell by 6% to Rs17.3 billion.

The company said that prices in the German generics market fell further as a result of a higher pace of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapeutic Category

Actithera Raises $75m To Enter Competitive FAP-Targeting Radioligand Field

 
• By Andrew McConaghie

While companies such as Eli Lilly and Roche have faced setbacks to their fibroblast activation protein-targeting oncology therapies, Actithera believes its radiopharmaceuticals platform will prove more successful.

J&J Seeks Schizophrenia Relapse Indication For Caplyta

 
• By Jessica Merrill

The company is expecting US FDA approval of the drug in a bigger indication, major depressive disorder, later this year.

Stock Watch: US CAR-T And Vaccine Actions: Net Negative For Access

 
• By Andy Smith

Relaxing CAR-T restrictions may not be an access panacea because of patient fragility and lack of payer incentive. Conversely, the ACIP’s recent recommendation on Thiomersal-containing flu vaccines is probably the thin edge of a more restrictive wedge.